Dainippon Sumitomo sales and marketing update

Dainippon's Sunovion Pharmaceuticals Inc. subsidiary launched Aptiom eslicarbazepine acetate in the U.S. as an add-on therapy to treat partial-onset seizures in adult epileptics. The wholesale acquisition cost (WAC) for a 30-count package of 400 or 800 mg tablets is $599.40; $1,198.80 for a 60-count package of 600 mg tablets; and $449.70 for a 30-count package of 200 mg tablets. According to Aptiom's label, the recommended maintenance dose is 800 mg once daily and the maximum maintenance dose is 1,200 mg once daily. The recommended maintenance dose in patients with moderate to severe renal impairment is 400 mg once daily, with a maximum maintenance dosage of 600 mg once daily. ...